XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Note 3 - Revenue
6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

3.

Revenue

 

On February 2, 2022, the Company announced an addendum to the 2019 Janssen Manufacturing Agreement XBiotech will continue to manufacture bermekimab for use by Janssen in its clinical trials through December 2023. For the three months and six months ended June 30, 2022, the Company has recorded $1.5 and $2.0 million, respectively of gross revenue under the February 2022 agreement.